Nathalie Q. T.
- Country
- France
- Department
- Oncologue
Research Overview
- Phase 2 Randomized Open-Label Study of BDC-1001 Monotherapy and Combination with Pertuzumab in HER2-Positive Metastatic Breast Cancer Post-Trastuzumab Deruxtecan
- Phase III Study on Palbociclib with Anti-HER2 and Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer Post-Induction Treatment
- Phase III Evaluation of Sacituzumab Govitecan Versus Physician's Choice in HER2-Negative Breast Cancer with High Relapse Risk Post-Neoadjuvant Therapy
Data & Insights
Has run more than one trial at 36 of 171 partner sites.
Specializations
Advanced Breast Cancer Treatment
The investigator specializes in treating HER2-positive metastatic breast cancer, conducting research on innovative therapeutic combinations involving tucatinib and established treatments like pertuzumab and trastuzumab.
- Metastatic Disease Management
- HER2-Targeted Therapies
- Combination Treatment Approaches
Focuses on developing treatment strategies for unresectable locally-advanced breast cancer cases.
High-Risk Breast Cancer
Investigates novel approaches for high-risk HER2-positive breast cancer patients, particularly examining the effectiveness of Trastuzumab Deruxtecan compared to established treatments in post-neoadjuvant settings.
- Residual Disease Treatment
- Post-Neoadjuvant Therapy
- Treatment Optimization
Specializes in evaluating innovative therapeutic options for resistant disease.
Targeted Therapeutic Innovation
Explores cutting-edge treatments including sacituzumab govitecan for HER2-negative breast cancer and novel agents like BDC-1001 for previously treated cases.
- Novel Drug Development
- Treatment Resistance
- Precision Medicine Approaches
Evaluates emerging therapeutic options for various breast cancer subtypes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.